CODX Quote, Financials, Valuation and Earnings

CareDx, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of 1.67%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat CareDx, Inc.'s return on equity of 21.1%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 300.53%. On the other hand CareDx, Inc. has an analysts' consensus of $22.33 which suggests that it could grow by 20.53%. Given that Co-Diagnostics, Inc. has higher upside potential than CareDx, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than CareDx, Inc..

Co-Diagnostics, Inc. has a beta of 1.149, which suggesting that the stock is 14.942% more volatile than S&P 500. In comparison CareDx, Inc. has a beta of 2.544, suggesting its more volatile than the S&P 500 by 154.38%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CareDx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. CareDx, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than CareDx, Inc. quarterly revenues of $100.1M. Co-Diagnostics, Inc.'s net income of -$5.9M is lower than CareDx, Inc.'s net income of $1.7M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while CareDx, Inc.'s PE ratio is 15.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 25.09x versus 2.87x for CareDx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pulmonx Corp. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -64.91%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Pulmonx Corp.'s return on equity of -73.42%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 300.53%. On the other hand Pulmonx Corp. has an analysts' consensus of $5.75 which suggests that it could grow by 186.07%. Given that Co-Diagnostics, Inc. has higher upside potential than Pulmonx Corp., analysts believe Co-Diagnostics, Inc. is more attractive than Pulmonx Corp..

Co-Diagnostics, Inc. has a beta of 1.149, which suggesting that the stock is 14.942% more volatile than S&P 500. In comparison Pulmonx Corp. has a beta of 0.219, suggesting its less volatile than the S&P 500 by 78.135%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulmonx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Pulmonx Corp. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than Pulmonx Corp. quarterly revenues of $21.5M. Co-Diagnostics, Inc.'s net income of -$5.9M is higher than Pulmonx Corp.'s net income of -$14M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Pulmonx Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 25.09x versus 0.88x for Pulmonx Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -735.19%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 300.53%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 133.42%. Given that Co-Diagnostics, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than Intellia Therapeutics, Inc..

Co-Diagnostics, Inc. has a beta of 1.149, which suggesting that the stock is 14.942% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Co-Diagnostics, Inc.'s net income of -$5.9M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 25.09x versus 17.51x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -27.41%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 300.53%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $35.63 which suggests that it could grow by 10.29%. Given that Co-Diagnostics, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Co-Diagnostics, Inc. is more attractive than Twist Bioscience Corp..

Co-Diagnostics, Inc. has a beta of 1.149, which suggesting that the stock is 14.942% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.157%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than Twist Bioscience Corp. quarterly revenues of $99M. Co-Diagnostics, Inc.'s net income of -$5.9M is higher than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 25.09x versus 5.16x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.